intralesional injection of hyaluronic acid in patients affected with peyronie's disease: preliminary results from a prospective, multicenter, pilot study
Clicks: 291
ID: 144131
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
291 views
48 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #10 of 27 articles by views in australian journal of chemistry
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Introduction: Hyaluronic acid has been shown to be efficacious in decreasing scar formation, inflammation, and oxidative stress.
Aim: To assess the efficacy of intralesional injection of hyaluronic acid in patients affected by Peyronie's disease.
Methods: In this prospective, single-arm, self-controlled, interventional, multicenter pilot study, 65 patients underwent a 10-week cycle of weekly intraplaque injections with hyaluronic acid (0.8% highly purified sodium salt hyaluronic acid 16 mg/2 mL; Sinovial, IBSA, Lodi, Italy). Patients were re-evaluated 2 months after the end of therapy.
Main Outcome Measures: Plaque size (millimeters), penile curvature (degrees), International Index of Erectile Function (IIEF-5) score, visual analog scale (VAS) score for sexual satisfaction, and Patient's Global Impressions of Improvement (PGI-I) score.
Results: Median age was 57 years (range = 23–70). At baseline, mean plaque size was 10 mm (range = 3–30 mm), mean penile curvature was 30° (range = 0°–50°), and mean IIEF-5 score was 20 (range = 0–25), with slight to moderate erectile dysfunction (IIEF score < 21) in 36 of 65 patients (55%). A median VAS score of 6 (range = 2–10) was found. Mean follow-up was 12 months (range = 6–24 months). Statistically significant post-treatment improvements were detected for plaque size (before treatment = 10 mm [3–30 mm], after treatment = 8 mm [1–30 mm], P < .0001), penile curvature (before treatment = 30° [0°–50°], after treatment = 20° [0°–40°], P < .0001), IIEF-5 score (before treatment = 20 [11–25], after treatment = 21 [15–25], P < .0001), and VAS score (before treatment = 6 [2–10], after treatment 8 [2–10], P < .0001). After treatment, the rate of patients with an IIEF score lower than 21 decreased from 55% (36 patients) to 40% (25 patients). Overall improvement on the PGI-I questionnaire was 69%.
Conclusion: Intralesional treatment with hyaluronic acid can improve plaque size, penile curvature, and overall sexual satisfaction and seems preferably indicated in the early (active) phase of the disease. Furthermore, it is easy to perform and well tolerated.
| Reference Key |
md2016sexualintralesional
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Alessandro Zucchi, MD;Elisabetta Costantini, MD;Tommaso Cai, MD;Giorgio Cavallini, MD;Giovanni Liguori, MD;Vincenzo Favilla, MD;Gaetano De Grande, MD;Giuseppe D'Achille, MD;Mauro Silvani, MD;Giorgio Franco, MD;Alessandro Palmieri, MD;Paolo Verze, MD, PhD;Vincenzo Mirone, MD |
| Journal | australian journal of chemistry |
| Year | 2016 |
| DOI |
10.1016/j.esxm.2016.01.002
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.